Catherine Ulbricht
Harvard University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Catherine Ulbricht.
Clinical Journal of The American Society of Nephrology | 2007
Steven Gabardi; Kristin Munz; Catherine Ulbricht
Complementary and alternative medicine (CAM) is a multibillion-dollar industry. Almost half of the American population uses some form of CAM, with many using them in addition to prescription medications. Most patients fail to inform their health care providers of their CAM use, and physicians rarely inquire. Annually, thousands of dietary supplement-induced adverse events are reported to Poison Control Centers nationwide. CAM manufacturers are not responsible for proving safety and efficacy, because the Food and Drug Administration does not regulate them. However, concern exists surrounding the safety of CAM. A literature search using MEDLINE and EMBASE was undertaken to explore the impact of CAM on renal function. English-language studies and case reports were selected for inclusion but were limited to those that consisted of human subjects, both adult and pediatric. This review provides details on dietary supplements that have been associated with renal dysfunction and focuses on 17 dietary supplements that have been associated with direct renal injury, CAM-induced immune-mediated nephrotoxicity, nephrolithiasis, rhabdomyolysis with acute renal injury, and hepatorenal syndrome. It is concluded that it is imperative that use of dietary supplements be monitored closely in all patients. Health care practitioners must take an active role in identifying patients who are using CAM and provide appropriate patient education.
Expert Opinion on Drug Safety | 2005
Catherine Ulbricht; Ethan Basch; Heather Boon; Edzard Ernst; Paul Hammerness; David Sollars; Candy Tsourounis; Jen Woods; Stephen Bent
This systematic review discusses the proposed uses, dosing parameters, adverse effects, toxicology, interactions and mechanism of action of kava. The widespread concern regarding the potential hepatotoxicity of kava is discussed. A recommendation is made to consolidate and analyse available reports and to continue postmarket surveillance in an international repository to prevent duplicates and promote collection of thorough details at the time of each report so that any association with kava is clearly defined.
Journal of Herbal Pharmacotherapy | 2008
Catherine Ulbricht; Jennifer Armstrong; Ethan Basch; Samuel Basch; Steve Bent; Cynthia Dacey; Sean Dalton; Ivo Foppa; Nicole Giese; Paul Hammerness; Catherine DeFranco Kirkwood; David Sollars; Shaina Tanguay-Colucci; Wendy Weissner
An evidence-based systematic review including written and statistical analysis of scientific literature, expert opinion, folkloric precedent, history, pharmacology, kinetics/dynamics, interactions, adverse effects, toxicology, and dosing.
Journal of Dietary Supplements | 2011
Catherine Ulbricht; Julie Conquer; Dawn Costa; Whitney Hollands; Carmen M. Iannuzzi; Richard Isaac; Joseph K. Jordan; Natalie Ledesma; Cathy Ostroff; Jill M. Grimes Serrano; Michael Shaffer; Minney Varghese
ABSTRACT An evidence-based systematic review including written and statistical analysis of scientific literature, expert opinion, folkloric precedent, history, pharmacology, kinetics/dynamics, interactions, adverse effects, toxicology, and dosing.
Journal of Herbal Pharmacotherapy | 2008
Catherine Ulbricht; Ethan Basch; Dilys Burke; Lisa Cheung; Edzard Ernst; Nicole Giese; Ivo Foppa; Paul Hammerness; Sadaf Hashmi; Grace M. Kuo; Michelle Miranda; Siddhartha Mukherjee; Michael Smith; David Sollars; Shaina Tanguay-Colucci; N. Vijayan; Wendy Weissner
An evidence-based systematic review including written and statistical analysis of scientific literature, expert opinion, folkloric precedent, history, pharmacology, kinetics/dynamics, interactions, adverse effects, toxicology and dosing. doi:10.1300/J157v07n03_06 [Article copies available for a fee from The Haworth Document Delivery Service: 1–800-HAWORTH. E-mail address: <[email protected]> Website: <http://www.HaworthPress.com>]
Journal of Herbal Pharmacotherapy | 2007
Ethan Basch; Steve Bent; Ivo Foppa; Sadaf Haskmi; David S. Kroll; Michelle Mele; Philippe Szapary; Catherine Ulbricht; Mamta Vora; Sophanna Yong
An evidence-based systematic review including written and statistical analysis of scientific literature, expert opinion, folkloric precedent, history, pharmacology, kinetics/dynamics, interactions, adverse effects, toxicology and dosing.
Journal of Herbal Pharmacotherapy | 2004
Ethan Basch; Heather Boon; Theresa Davies-Heerema; Ivo Foppo; Sadaf Hashmi; Jens Hasskarl; David Sollars; Catherine Ulbricht
An evidence-based systematic review including written and statistical analysis of scientific literature, expert opinion, folkloric precedent, history, pharmacology, kinetics/dynamics, interactions, adverse effects, toxicology, and dosing.
Journal of Herbal Pharmacotherapy | 2006
Ethan Basch; Steve Bent; Ivo Foppa; Sadaf Haskmi; David S. Kroll; Michelle Mele; Philippe Szapary; Catherine Ulbricht; Mamta Vora; Sophanna Yong
An evidence-based systematic review including written and statistical analysis of scientific literature, expert opinion, folkloric precedent, history, pharmacology, kinetics/dynamics, interactions, adverse effects, toxicology and dosing.
Journal of Dietary Supplements | 2010
Catherine Ulbricht; Tracee Rae Abrams; Ashley Brigham; James Ceurvels; Jessica Clubb; Whitney Curtiss; Catherine DeFranco Kirkwood; Nicole Giese; Kevin Hoehn; Ramon Iovin; Richard Isaac; Erica Rusie; Jill M. Grimes Serrano; Minney Varghese; Wendy Weissner; Regina C. Windsor
ABSTRACT An evidence-based systematic review of rosemary (Rosmarinus officinalis), including written and statistical analysis of scientific literature, expert opinion, folkloric precedent, history, pharmacology, kinetics/dynamics, interactions, adverse effects, toxicology, and dosing.
Journal of The Society for Integrative Oncology | 2007
Ethan Basch; Steve Bent; Jeffrey R. Collins; Cynthia Dacey; Paul Hammerness; Michelle Harrison; Michael Smith; Philippe Szapary; Catherine Ulbricht; Mamta Vora; Wendy Weissner
The objective of this study was to evaluate the scientific evidence on flaxseed, including expert opinion, folkloric precedent, history, pharmacology, kinetics/dynamics, interactions, adverse effects, toxicology, and dosing. Electronic searches were conducted in 9 databases, 20 additional journals (not indexed in common databases), and bibliographies from 50 selected secondary references. No restrictions were placed on the language or quality of the publications. All literature collected pertained to efficacy in humans, dosing, precautions, adverse effects, use in pregnancy/lactation, interactions, alteration of laboratory assays, and mechanisms of action. Standardized inclusion/exclusion criteria are used for selection. Grades were assigned using an evidence-based grading rationale. A review of the literature on flaxseed yielded 13 categories for which flaxseed had been studied in humans, including constipation/laxative, attention-deficit hyperactivity disorder, hyperlipidemia, atherosclerosis/coronary artery disease, breast cancer, cyclic mastalgia (breast pain), menopausal symptoms, hyperglycemia/diabetes, hypertension, lupus nephritis, human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS), and prostate cancer. Most of the available evidence investigates the efficacy of alpha-linoleic acid found in flaxseed compared with fish oil, and almost all of the available studies are poor quality. Although flaxseed and flaxseed oil have several promising future uses, the available literature does not support recommendation for any condition at this time.